Acarbose and growth of China diabetes management

doi:10.3969/j.issn.1004-583X.2016.01.001

Abstract

Abstract: Over the past 20 years, diabetes management philosophy continually has updated with the progress. Meanwhile, acarbose (Glucobay) came on market, and entered into clinical applications of China, its treatment philosophy fits the development of diabetes management concept, such as “pay attention to postprandial blood glucose, reduce blood sugar fluctuations”, “prevention of diabetes, as soon as possible intervention” and so on. This paper focuses on the diabetes management philosophy and acarbose application history in China.

Key words: diabetes mellitus,type 2, acarbose

CLC Number:

R587.1

Yang Wenying. Acarbose and growth of China diabetes management[J]. Clinical Focus, 2016, 31(1): 1-6.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.001

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/1

References

[1] Kahn SE, Cooper ME, Del Prato S.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future[J]. Lancet, 2014, 383(9922): 1068-1083.
[2] Qiao Q, Nakagami T, Tuomilehto J, et al.International Diabetes Epidemiology Group; DECODA Study Gro.Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts[J]. Diabetologia, 2000,43(12):1470-1475.
[3] Wang JS, Tu ST, Lee IT,et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring[J]. Diabetes Metab Res Rev, 2011,27(1):79-84.
[4] International Diabetes Federation.2011 Guideline for Management of PostMeal Glucose in Diabetes[EB/OL].http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes.
[5] Torimoto K, Okada Y, Mori H, et al. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus[J].Cardiovasc Diabetol, 2013,12:1.
[6] International Diabetes Federation.2007 Guideline for Management of PostMeal Glucose in Diabetes[EB/OL]. http://www.idf.org/guidelines/postmeal-glucose-2007.
[7] Pan CY, Landen H.Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China[J]. Clin Drug Investig, 2007,27(6):397-405.
[8] 陈璐璐,郑涓. 阿卡波糖、二甲双胍、格列吡嗪在新诊断青年2型糖尿病患者中应用的比较[J].中华内分泌代谢杂志, 2004,20(5)449-450.
[9] Ju-Ming L, Xiao-Hui G, Xiao-Feng L, et al. Effects of Nateglinide on Postprandial Plasma Glucose Excursion and Metabolism of Lipids in Chinese Patients with Type 2 Diabetes:a 4-week, randomized, active-control, open-label, parallel-group, multicenter trial[J]. Curr Med Res Opin, 2012 Jul 19. [Epub ahead of print]
[10] Koyasu M, Ishii H, Watarai M, et al.Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease[J]. Clin Ther, 2010,32(9):1610-1617.
[11] Salman S, Salman F, Satman I, et al.Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes[J]. Curr Med Res Opin, 2001,16(4):296-306.
[12] Yang W, Liu J, Shan Z, et al.Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial[J]. Lancet Diabetes Endocrinol, 2014,2(1):46-55.
[13] Bao YQ, Zhou J, Zhou M, et al.Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed type 2 diabetes[J]. Clin Exp Pharmacol Physiol, 2010,37(5/6):564-568.
[14] Tabák AG, Herder C, Rathmann W,et al.Prediabetes: a high-risk state for diabetes development[J]. Lancet, 2012,379(9833):2279-2290.
[15] Task Force Members, Rydén L, Grant PJ,,et al.ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)[J]. Eur Heart J, 2013,34(39):3035-3087.
[16] Li G, Zhang P, Wang J, et al.Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study[J]. Lancet Diabetes Endocrinol, 2014,2(6):474-480.
[17] Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group.Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362(12):1090-1101.
[18] Zhou X, Qiao Q, Ji L, et al.Nonlaboratory-based risk assessment algorithm for undiagnosed type 2 diabetes developed on a nation-wide diabetes survey[J]. Diabetes Care, 2013,36(12):3944-3952.
[19] 陈韵岱,李丹丹,董蔚,等.冠心病和高血压患者中糖代谢异常的门诊筛查流程及现状调查[J].中华心血管病杂志,2013,41(12) 995-999.
[20] Pan CY, Gao Y, Chen JW, et al.Efficacy of acarbose in Chinese subjects with impaired glucose tolerance[J]. Diabetes Res Clin Pract, 2003,61(3):183-190.
[21] Chiasson JL, Josse RG, Gomis R, et al.Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial[J]. Lancet, 2002,359(9323):2072-2077.
[22] Ji L, Hu D, Pan C, Weng J,et al. CCMR Advisory Board; CCMR-3B STUDY Investigators.Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J]. Am J Med, 2013,126(10):925.e11-22.
[23] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014, 6(7):447-498.
[24] American Diabetes Association.Standards of medical care in diabetes--2014[J].Diabetes Care,2014,37( Suppl 1):S14-80.
[25] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group[J]. N Engl J Med, 1993,329(14):977-986.
[26] UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J]. Lancet, 1998,352(9131):837-853.
[27] ADVANCE Collaborative Group, Patel A, MacMahon S, et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group[J]. N Engl J Med, 2008,358(24):2560-25672.
[28] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.Effects of intensive glucose lowering in type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group[J]. N Engl J Med, 2008,358(24):2545-2559.
[29] Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013 UK Prospective Diabetes Study (UKPDS) Group[J]. Endocr Pract, 2013,19(2):327-336.
[30] Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial[J]. JAMA, 2003,290(4):486-494.
[31] Wang H, Ni Y, Yang S, et al.The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus[J]. Curr Ther Res Clin Exp, 2013,75:88-92.
[32] Jayaram S, Hariharan RS, Madhavan R,et al.A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes[J]. J Assoc Physicians India, 2010,58:679-82, 687.
[33] Rosak C, Hofmann U, Paulwitz O.Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application[J]. Diabetes Nutr Metab, 2004,17(3):137-142.
[34] Schnell O, Mertes G, Standl E,et al.Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy[J]. Diabetes Obes Metab, 2007,9(6):853-858.
[35] Duran C, Tuncel E, Ersoy C, et al.The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese type 2 diabetic patients[J]. J Endocrinol Invest, 2009,32(1):69-73.
[36] Liu SC, Tu YK, Chien MN, et al.Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis[J]. Diabetes Obes Metab, 2012,14(9):810-820.
[37] Rosak C, Haupt E, Walter T, et al.The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia[J]. Diabetes Nutr Metab, 2002,15(3):143-151.
[38] Hwu CM, Ho LT, Fuh MM, et al.Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study[J]. Diabetes Res Clin Pract, 2003,60(2):111-118.
[39] 中国胰岛素分泌研究组,安雅莉,高妍,等. 中国新诊断2型糖尿病胰岛素分泌和胰岛素抵抗特点调查[J].中华内分泌代谢杂志,2008,24(3):256-260.
[40] 潘长玉,姬秋和,杨文英,等.2型糖尿病患者维格列汀与阿卡波糖单药治疗的比较研究24周多中心、随机、双盲、双模拟、阳性对照试验[J].中华内分泌代谢杂志, 2009,25(4):386-390.
[41] En FY, Imeryüz N, Akin L, et al.Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release[J]. Am J Physiol Gastrointest Liver Physiol, 2001,281(3):G752-763.
[42] Su B, Liu H, Li J, et al.Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes, 2015,7(5):729-739.